GPCR and Calcium Signaling Mechanisms and Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/40

flashcard set

Earn XP

Description and Tags

Comprehensive practice flashcards detailing key terminology, signaling cascades, receptor pharmacology, and structural biology principles of GPCR and calcium second messenger signaling.

41 Terms

1
New cards

In calcium-mediated cellular responses what is needed for the release of Ca

Hormone stimulation leads to IP₃ production, which releases Ca²⁺ from

endoplasmic reticulum stores


2
New cards

example of Calcium-mediated cellular responses (picture)

knowt flashcard image
3
New cards

Phospholipase C (PLC) activated by GP couple receptors

An enzyme activated by GPCRs that cleaves the membrane lipid PIP2\text{PIP}_2 into two second messengers: IP3\text{IP}_3 and DAG.

4
New cards

Inositol 1,4,5-trisphosphate (IP3\text{IP}_3)

A water-soluble second messenger produced by PIP2\text{PIP}_2 cleavage that diffuses through the cytoplasm to bind ER receptors and trigger the rapid release of stored Ca2+\text{Ca}^{2+}.

5
New cards

Diacylglycerol (DAG)

A lipid-derived second messenger generated by PLC cleavage that remains anchored in the plasma membrane to activate Protein Kinase C (PKC).

6
New cards

Protein Kinase C (PKC)

A kinase that translocates to the plasma membrane upon intracellular Ca2+\text{Ca}^{2+} elevation

  • activated by DAG, Ca 2+ and phosphatidylserine to phosphorylate serine and threonine residues.


7
New cards

what occurs during IP3-mediated Calcium release

  • IP3​ binds to IP3 receptors on the ER membrane, opening channels to rapidly release stored Ca2+

  • The surge in cytoplasmic Ca2+ activates calcium-binding proteins, such as calmodulin, which then regulate enzymes, ion channels, and cytoskeletal proteins.


<ul><li><p><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;">IP3​</span><span> binds to </span><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;">IP3 </span><span>receptors on the <strong>ER membrane,</strong> opening channels to rapidly release stored </span><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;">Ca2+</span></p></li><li><p><span>The surge in <strong>cytoplasmic </strong></span><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><strong>Ca2+</strong></span><span><strong> </strong>activates calcium-binding proteins, such as calmodulin, which then regulate enzymes, ion channels, and cytoskeletal proteins.</span></p></li></ul><p></p>
8
New cards

Voltage-Dependent Anion Channels (VDACs) - CA2+ related

Outer mitochondrial membrane channels physically linked to ER IP3Rs\text{IP}_3\text{Rs} via GRP75 proteins that transfer released Ca2+\text{Ca}^{2+} from mitochondria-associated membranes (MAMs) into the intermembrane space.

9
New cards

Mitochondrial Ca2+\text{Ca}^{2+} Uniporter (MCU)

An inner mitochondrial membrane channel opened by high Ca2+\text{Ca}^{2+} concentrations in the intermembrane space, allowing Ca2+\text{Ca}^{2+} to enter the mitochondrial matrix and stimulate ATP synthesis.

10
New cards

when Ca is too high in the matrix…

Step 4: Ca2+ - Released from matrix into the intermembrane space over time by inner membrane (NCLX) and Ca2+/H+ (HCX) antiporters to prevent Ca2+ toxicity. VDAC transfers intermembrane space Ca2+ into the cytosol.

Step 5: ER membrane Ca2+-ATPases pump Ca2+ from the cytosol into the ER – restores high ER Ca2+


<p>Step 4: Ca2+ - Released from matrix into the intermembrane space over time by inner membrane (NCLX) and Ca2+/H+ (HCX) <strong><mark data-color="yellow" style="background-color: yellow; color: inherit;">antiporters </mark></strong>to prevent Ca2+ toxicity. VDAC transfers intermembrane space Ca2+ into the cytosol.</p><p>Step 5: ER membrane Ca2+-ATPases pump Ca2+ from the cytosol into the ER – restores high ER Ca2+</p><p></p>
11
New cards

STIM1 - opening of store-operated Ca2+

An ER transmembrane protein with luminal EF hand domains that senses ER Ca2+\text{Ca}^{2+} levels;

  • binding of STIM1 to EB1 traps the STMI1

  • as ER stores are depleted it dissociates from EB1, oligomerizes, and migrates to ER-plasma membrane junctions.


12
New cards

Orai1

A store-operated Ca2+\text{Ca}^{2+} channel located in the plasma membrane that is opened by the CAD domains of oligomerized STIM1 to permit extracellular Ca2+\text{Ca}^{2+} into the cytosol.

13
New cards

Glycogen Phosphorylase Kinase (GPK)

A regulatory metabolic enzyme coordinated synergistically by both hormonal signals (cAMP\text{cAMP} via PKA) and neural/vasopressin signals (Ca2+\text{Ca}^{2+} via calmodulin subunits) to stimulate glycogen breakdown.

<p>A regulatory metabolic enzyme coordinated synergistically by both hormonal signals ($$\text{cAMP}$$ via PKA) and neural/vasopressin signals ($$\text{Ca}^{2+}$$ via calmodulin subunits) to stimulate glycogen breakdown.</p>
14
New cards

side note: are GPCRS integral proteins and are they the largest family of membrane receptors?

yes

15
New cards

Orthosteric Binding Site (OBS) - activation of most GPCRS

The primary endogenous ligand-binding pocket of a GPCR that mediates receptor activation and stabilizes its active conformation.

16
New cards

other ways of GPCR activation (ligand independent)

  • light induced isomerizatioon (rhodospins)

  • proteolytic cleavage (PARs)

  • biophysical processes (pH)


17
New cards

Inverse Agonist - GPCR Ligand Classification

A ligand that decreases or abolishes basal constitutive GPCR signaling activity by stabilizing the receptor in an inactive conformation.

18
New cards

orthosteric ligands vs allosteric ligands

Orthosteric ligands binds directly to the primary active site whereas Allosteric ligands bind away from active site


<p>Orthosteric ligands binds directly to the primary active site whereas Allosteric ligands bind away from active site</p><p></p>
19
New cards

Biased Agonism

The ability of specific ligands to selectively engage distinct downstream signaling pathways (such as G protein activation over β\beta-arrestin recruitment) at the expense of others.

20
New cards

Oliceridine

A G protein-biased agonist targeting the μ\mu-opioid receptor that actiates G protein signalling and minimizes β\beta-arrestin signaling to produce analgesia with reduced adverse side effects like respiratory depression and constipation.

  • Oliceridine gives pain relief with reduced effects!


21
New cards

TRV027

A β\beta -arrestin-biased agonist targeting the angiotensin II receptor (AT1R\text{AT}_1\text{R}) that was evaluated in the BLAST-AHF trial for acute heart failure but discontinued after failing to surpass placebo efficacy.

22
New cards

Tachyphylaxis

A rapid decrease in receptor responsiveness following repeated or sustained agonist stimulation, presenting a key therapeutic obstacle in the treatment of chronic disorders.

  • when drugs stop working


23
New cards

Tachyphylaxis and Ligand-Receptor Kinetics

tachyphylaxis is primarily driven by the ligand's dissociation rate (koff) rather than β-arrestin-mediated desensitization.

  • High residence time agonists (low koff): Allow internalized receptors to remain active, promoting sustained signaling from endosomes.

  • Low residence time agonists: Dissociate during internalization, confining receptor activation to the plasma membrane and reducing tachyphylaxis.


24
New cards

Allosteric Modulators (AMs) - dealing with Tachypylaxis

Ligands that bind to to distinct sites, then the orthosteric binding site, fine-tuning the affinity or efficacy of orthosteric compounds with improved subtype specificity.

25
New cards

PAM vs NAM

PAM (Positive Allosteric Modulator) enhances the effects of orthosteric ligands

NAM (Negative Allosteric Modulator) reduces or inhibits their effects, creating a nuanced approach to pharmacological manipulation.

26
New cards

Cmpd-6

A positive allosteric modulator (PAM) of the β2\beta_2-adrenergic receptor (β2AR\beta_2\text{AR}) that amplifies agonist efficacy while reducing the susceptibility to receptor tachyphylaxis.

27
New cards

DETQ

A positive allosteric modulator (PAM) for the dopamine D1R\text{D}_1\text{R} that sustains locomotor activity over repeated administration without inducing the rapid tachyphylaxis caused by direct orthosteric agonists.

28
New cards

Biased Allosteric Modulators (BAMs)

Molecules that merge allosteric modulatory capability with selective signalling

  • results in tailored cell response with reduced adverse effects


29
New cards

SBI-553

A β\beta-arrestin-biased allosteric modulator of the neurotensin 1 receptor (NTSR1) that promotes receptor internalization over Gq\text{G}_q activation, eliminating side effects like hypothermia and hypotension.

30
New cards

Bitopic Ligand

ligans simultaneously occupy both the orthosteric binding site and an allosteric pocket on the same GPCR protomer to enhance affinity, selectivity, and residence time.

31
New cards

Tiotropium

A long-acting M3\text{M}_3 antagonist prescribed for COPD that acts as a bitopic ligand by engaging both orthosteric and secondary binding sites simultaneously.

32
New cards

Bitopic ligand design (MOR)

Structural design of μ-opioid receptor (MOR) bitopic ligands involved linking a fentanyl moiety (orthosteric) to a guanidine group targeting the intramembrane sodium binding pocket (allosteric)

33
New cards

Bivalent Ligands

Dual-action compounds containing two distinct pharmacophoric moieties spaced by a linker to engage both protomers of a GPCR homodimer or heterodimer simultaneously.

  • GPCR Dimerization provides a mechanism for biased signaling and crosstalk regulation


<p>Dual-action compounds containing two distinct <strong>pharmacophoric moieties spaced by a linker to engage both protomers of a GPCR</strong> homodimer or heterodimer simultaneously.</p><ul><li><p><strong>GPCR Dimerization provides a mechanism for biased signaling and crosstalk regulation </strong></p></li></ul><p></p>
34
New cards

Endomembrane Signaling

Localized GPCR signaling originating from intracellular membrane compartments (including endosomes, the Golgi complex, and mitochondria) following receptor internalization.

  • enables cells to have flexibility in downstream sustained signaling responses in both time and space

  • parathyroid hormone receptor was the first GPCR driven by endosomal siganling


35
New cards

Current models of GPCR signaling from endomembranes

PTH1R:

  • Internalized via β-arrestin

  • β-Arrestin stays bound at endosome to scaffold G protein

  • Drives sustained signaling; terminated by retromer

    • TSHR:

  • Internalized via ββ-arrestin; arrestin dissociates at endosome

  • Retromer mediates retrograde transport to Golgi/TGN

  • Activates second phase of signaling at Golgi

    • B2AR (β2​AR):

  • β-arrestin engagement drives internalization

  • Initiates second phase of signaling from endosomes

  • Retromer rapidly recycles receptor to plasma membrane

    • B1AR (β1​AR):

  • Localized at both plasma membrane and Golgi

  • Golgi activation requires no receptor trafficking

  • Activated at Golgi by ligands entering via transporters


<p><strong>PTH1R</strong>:</p><ul><li><p>Internalized via <span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><em>β</em></span>-arrestin</p></li><li><p><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><em>β</em></span>-Arrestin stays bound at endosome to scaffold G protein</p></li><li><p>Drives sustained signaling; terminated by retromer</p><ul><li><p><strong>TSHR</strong>:</p></li></ul></li><li><p>Internalized via <span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;">β<em>β</em></span>-arrestin; arrestin dissociates at endosome</p></li><li><p>Retromer mediates retrograde transport to Golgi/TGN</p></li><li><p>Activates second phase of signaling at Golgi</p><ul><li><p><strong>B2AR</strong> (<span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><em>β</em>2​AR</span>):</p></li></ul></li><li><p><span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><em>β</em></span>-arrestin engagement drives internalization</p></li><li><p>Initiates second phase of signaling from endosomes</p></li><li><p>Retromer rapidly recycles receptor to plasma membrane</p><ul><li><p><strong>B1AR</strong> (<span style="font-family: KaTeX_Main, &quot;Times New Roman&quot;, serif; line-height: 1.2; font-size: 1.21em;"><em>β</em>1​AR</span>):</p></li></ul></li><li><p>Localized <strong>at both plasma membrane and Golgi</strong></p></li><li><p>Golgi activation requires no receptor trafficking</p></li><li><p>Activated at Golgi by ligands entering via transporters</p></li></ul><p></p>
36
New cards

Cell-Permeant Antagonists

Lipophilic or amphipathic receptor blockers capable of moving through membranes to suppress pathogenic GPCR signaling occurring from within intracellular compartments like endosomes.

37
New cards

Benefits of targeting internalized GPCRs

Block pathogen:

  • Prevent endosomal signalling with disorders

  • access intracellular Pools (target GPCRs with intracellular localization)

  • mitigate tachyphlaxis


38
New cards

traditional SAR vs dynamic SAR (structural Dynamics Structure - activity relationship)

  • Traditional SAR:Assumes a relatively static picture of a molecule or rigid ligand-receptor lock-and-key model

  • Dynamic SAR: Recognizes that molecules, proteins, and catalysts (such as nanoparticles) undergo conformational flexibility, induced-fit adjustments, or reaction-induced morphological changes during function.


39
New cards

Microswitches

Conserved networks of amino acid residues within GPCR helices that flip between inactive and active states

40
New cards

key structural determinants of allosteric regulation (3)

  1. microswitches

  2. allosteric ions → stabilize inactive conformation

  3. membrane lipids


41
New cards

future perspective in drug delivery

knowt flashcard image